APAC Articaine Hydrochloride Market

Asia Pacific Articaine Hydrochloride Market Size & Growth (2022 to 2027):

As per the research report, the size of the Asia Pacific Articaine Hydrochloride market was valued at USD 0.18 billion in 2022 and is expected to reach USD 0.28 billion by 2027 to grow at 8.43% CAGR during the forecast period 2022 to 2027.

The increase in the adoption of articaine hydrochloride due to its rapid effect and better efficiency than other anesthetic drugs such as lidocaine has driven the market's growth for the past several years. In addition, Articaine is more effective than lidocaine in patients with hypokalemic sensory hyperstimulation due to its remarkable ability to diffuse through tissues. Although articaine is widely used as the preferred local anesthetic drug in the European and Canadian markets, the articaine hydrochloride industry is still in the niche stage. However, it is anticipated to increase in the future. Additionally, the increasing prevalence of dental disorders due to the high intake of junk food, the large senior population, the growing trend for cosmetic dentistry procedures, and improving disposable income are estimated to drive the growth of the APAC articaine hydrochloride market.

Increasing incidence of dental caries and advances in dental anesthetic drug delivery devices will support the market. According to the WHO, it is estimated that around 2.37 billion people suffer from dental caries that affect permanent teeth. Furthermore, according to a recent publication, it is reported that nearly 90% of Chinese adults suffered from periodontal disease with varying severity, where over 30% had severe periodontitis, especially 43.55% in the age group 65 to 74. Hence, the APAC population is dependent on dental surgery procedures for better oral hygiene, which is likely to provide lucrative market growth.

In addition, the increased use of articaine for dental surgeries and the increasing expenditure on dental treatment is also driving the market growth.

Some popular local anesthetics other than articaine are prilocaine, lidocaine, mepivacaine, and bupivacaine. However, its availability and usage as alternative products are likely to hamper the growth of the APAC articaine hydrochloride market during the forecast period. It also observed that over 90% of dental expenses were due to out-of-pocket costs for most APAC region population due to lack of adequate reimbursement policies, which will hinder people from getting dental procedures done. Therefore, it may challenge the market in the years to come.

This research report on the APAC Articaine Hydrochloride Market has been segmented and sub-segmented into the following categories:

By Application:

• Infiltration
• Nerve Block
• Others

By End User:

• Dental Clinics
• Hospitals
• Academic
• Research Institutes

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Australia Articaine Hydrochloride Market is one of the fastest-growing markets and will dominate the Asia-Pacific articaine hydrochloride market in the years to come, attributed to the high adoption of new technologies and its use of dental applications. . In Australia, about 72% of dentists use articaine as a local anesthetic. In addition, ongoing R&D activities related to articaine hydrochloride and dental procedures coupled with increasing disposable income provide a significant opportunity for market growth.

According to the FDI World Dental Federation, more than 80.23% of people in the Asia-Pacific region suffer from dental caries, including countries like India, Bangladesh, Nepal, Malaysia, and Indonesia. In addition, between 40.65% and 59.5% of the population of China and Australia suffer from dental caries. China, Japan, and India are other significant regions predicted to show exponential growth in the future.

The growing demand for articaine hydrochloride in India is due to the awareness of new uses and improved dental expenditure. In Asia-Pacific, India held an 8.85% market share in 2019. According to the recently released survey, it was indicated, India's average expenditure on dental disease per capita in US dollars was 0.145, against US 350 dollars as seen in USA and USD 458 for Icelanders.

The Chinese articaine hydrochloride market is expected to grow at a CAGR of 6.65% in 2020. In Asian countries, China is one of the largest producers of articaine hydrochloride, and its products are mainly exported to the regions of the Middle East and Europe. Therefore, articaine hydrochloride is used more and more by healthcare professionals today.

KEY MARKET PLAYERS

Top companies leading in the APAC Articaine Hydrochloride Market profiled in the report are 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U, Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc, Pierrel S.p.A, Sanofi, Septodont, Siegfried AG, and Sigma Aldrich.